Shark Tank fame and Executive Director of Emcure Pharmaceuticals, Namita Thapar said at the ET NOW Global Business Summit 2024 on February 10 that the company plans to go public within three months.
Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital.
In short term, markets may enter a phase of consolidation but in the longer run if the Indian economy continues to show resilience and corporate profitability stays strong, the market will definitely see newer highs, says Raghvendra Nath.
Short term midcap indices are more overbought since they moved first and therefore yes, they can pullback more but eventually they will perform better during a bull market, says Rohit Srivastava.
Five such companies which have firmed up their initial public offering (IPO) plans are Glenmark Lifesciences, a fully-owned arm of Glenmark Pharmaceuticals, the city-based bulk drugs firm Supriya Lifesciences, drug formulations firm Windlass Biotech, Bain Capital-backed Emcure Pharma and CX Partners-funded Veeda Clinical Research. According to investment-bankers, they are planning to mop up over Rs 7,000 crore in primary share sales.